中国·永兴集团(yx5978)有限公司-官方网站

Recently, Alessandro Manzoni Hospital in Lecco, Italy, successfully treated a patient with a rare and complex pseudoaneurysm of the brachiocephalic trunk using Endovastec™'s Custom-Made Hector™ Multi-Branch Thoracic Stent Graft System (Hector™ (Custom-Made)). The procedure marked the hospital's first total endovascular aortic arch repair with the Hector™ (Custom-Made). As one of Italy's leading clinical centers for the diagnosis and treatment of aortic diseases, Manzoni Hospital has extensive expertise in minimally invasive aortic interventions. The successful procedure represents an important breakthrough in the hospital's treatment of complex aortic diseases using minimally invasive techniques and further reinforces the clinical adoption of the Hector™ (Custom-Made).

The clinical milestone attracted coverage from several local Italian media outlets. In their reports, Italian media highlighted the Hector™ (Custom-Made) as an advanced endovascular technology for the treatment of aortic arch diseases. Giovanni Rossi, Director of the Cardio-Thoracic-Vascular Department and Head of Vascular Surgery at ASST Lecco, noted that the introduction of this technology has further expanded the hospital's therapeutic offering, making it possible to successfully treat even frail patients or those with significant comorbidities.

The patient was a 74-year-old woman. Due to severe pulmonary complications, she could not undergo conventional open surgery requiring a median sternotomy. Following a comprehensive evaluation, the multidisciplinary team of Manzoni Hospital elected to carry out a totally endovascular minimally invasive procedure using Endovastec™'s Hector™ (Custom-Made). The stent graft was successfully implanted, and a follow-up CT scan performed one week after the procedure showed no complications. The patient recovered well and was subsequently discharged from the hospital.

Complex aortic arch disease remains one of the most challenging areas in endovascular therapy. Patients with diseases involving the aortic arch and its three supra-aortic branches face limited treatment options as the complex anatomy makes traditional surgical and endovascular treatments less suitable1. Complete endovascular reconstruction of the aortic arch, including all three supra-aortic branches, remains a significant clinical challenge. The Hector™ (Custom-Made) enables simultaneous endovascular reconstruction of the aortic arch and all three supra-aortic branches. It received an EU Quality Management System Certificate under MDR for its custom-made device in 2025 and has since been successfully used in customized clinical applications across multiple countries in Europe, Africa, and Southeast Asia.

In recent years, Endovastec™ has continued to advance globalization strategy by strengthening collaboration with international clinical experts and institutions while promoting the clinical application of its innovative product technologies worldwide. The successful application of the Hector™ (Custom-Made) at Manzoni Hospital, together with the attention it received from local Italian media, further demonstrates the value of Endovastec™'s innovative aortic intervention technologies in international clinical practice. Going forward, the Company will continue to expand treatment options for patients with complex aortic diseases around the world.

About Endovastec™

Founded in 2012, Endovastec™(Shanghai MicroPort Endovascular MedTech Group Co., Ltd.; SSE: 688016), a member of the MicroPort^® Group (MicroPort Scientific Corporation, HKEX: 00853), is a global medical device company focusing on the research, development, manufacturing, and commercialization of aortic, peripheral vascular and tumor interventional devices.

Endovastec™'s product portfolio includes thoracic and abdominal aortic stent grafts, surgical stent grafts, peripheral vascular stents, drug-coated balloon dilatation catheters, plain balloon dilatation catheters, vena cava filters, snare retrieval kits, thrombectomy devices, and tumor embolization microspheres. The company is committed to advancing emerging technologies in great vessel surgery and peripheral vascular medicine and to providing access to state-of-the-art solutions for patients worldwide.

For more information, please visit: www.Endovastec.com/en

Regulatory Disclaimer

Regulatory status varies by country and region. Healthcare professionals should refer to applicable local regulatory requirements and instructions for use.

References

⒈ Hybrid and Endovascular Management of Aortic Arch Pathology. J Clin Med. 2024 Oct 19;13(20):6248. DOI: 10.3390/jcm13206248